City News: Haleon posts strong growth in first listed results amid Zantac battle

Haleon logo

Former GSK consumer arm Haleon posted strong double-digit growth in its first financial results as a listed company, although investors were more interested in its tough stance against its former parent over Zantac litigation.

Already have an account? Sign in here

Want access to this article?

Register for LIMITED access

REGISTER FOR FREE

Get PREMIUM access for £1 a week

SUBSCRIBE NOW